Time is limited! Fill out the form on this page to see if you qualify.
An advocate or attorney will contact you within minutes for your free consultation.
No fees unless you are awarded compensation!
Tasigna (nilotinib) is a popular blood cancer drug used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs). Gleevec® (imatinib) was the first FDA-approved TKI to specifically target the BCR-ABL tyrosine kinase enzyme, a unique protein that spurs cancer cell growth. Drug companies developed second-generation TKIs like Tasigna, Sprycel® (dasatinib), Bosulif® (bosutinib), and Iclusig (ponatinib) to give leukemia patients additional treatment options.
In April 2013, Health Canada issued a drug safety warning after Tasigna clinical trials found an increased risk for developing coronary artery disease and other life-threatening heart problems. However, Tasigna’s manufacturer, Novartis AG, failed to issue a similar warning to American healthcare providers and consumers. In March 2016, the family of a California man who suffered a major stroke and died while taking Tasigna filed the first wrongful death lawsuit against Novartis. Due to the rapid onset of life-threatening heart problems, more patients are coming forward to file claims to get the justice and compensation they deserve.
